OPICAPONE
Get in touch with us!
Get in touch with us!
An Overview
ANTIPARKINSON THERAPY
Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson’s disease and end-of-dose motor fluctuations. It is a potent, reversible, and peripherally acting third-generation inhibitor of catechol-O-methyltransferase (COMT).
Description / Use
- Product type: catechol-O-methyl transferase inhibitor
- CAS number: 923287-50-7
- Common indications: parkinson
- Product status: development
- Available grades: on demand
Properties
- Oral administration
- Long action duration (24 h)
- Potential global treatment candidates about 4-5 million people
- CAGR (2023-2033) over +1.8%
Advantages
- Flow technology under development.
- European manufacturer.
- Total impurities around 0.1%.
- Purity > 98%.
- PV batches beg Q4 2026.
- DMF w/ 6 months stability end Q1 2027.
- Strong technical and IP knowledge.
- IP-driven PSD options.
Final Product Innovator Presentations
- 25 mg hard capsules.
- 50 mg hard capsules.
* Items covered by valid patents are not offered or supplied for commercial use. Products under patent are available for R&D use only.
Our API
Opicapone
- Our API opicapone is manufactured in accordance with cGMP and stringent international quality standards.
Quality
- Our quality control follows every stage from development of analytical methods to the control of manufacturing process, enabling us to achieve rigorous and stringent results in accordance with injectables parameters, even under aseptic conditions.